Truist analyst Joon Lee raised the firm’s price target on Verona Pharma (VRNA) to $76 from $57 and keeps a Buy rating on the shares after its Q4 earnings beat. The company’s prescriber base metrics shared imply continued launch momentum for Ohtuvayre, with 600 new prescriber adds per month, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma price target raised to $83 from $68 at Roth MKM
- Verona Pharma’s Strong Market Position and Growth Potential Drive Buy Rating
- Positive Outlook on Verona Pharma’s Ohtuvayre: Strong Sales, Strategic Positioning, and Growth Potential
- Verona Pharma price target raised to $93 from $74 at Wells Fargo
- Verona Pharma price target raised to $75 from $60 at H.C. Wainwright